Exciting News: CSL’s Game-Changing HAE Prevention Treatment, Andembry-Garadacimab, Receives Japanese Approval for Wide Use!
CSL Behring’s New Monoclonal Antibody Treatment ANDEMBRY® Receives Approval in Japan CSL Behring K.K., a leading global biotherapeutics company, recently made a significant breakthrough in the treatment of Hereditary Angioedema (HAE). The company announced that it has received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY® (garadacimab) Subcutaneous…